TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02286206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
Study: NCT01055314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study: NCT03171376

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment and coronal restoration
Description: After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment and coronal restoration
Description: After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
Study: NCT00316290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Parent Training
Description: Treatment will include behavioral parent training, a course on coping with depression, and cognitive-behavioral therapy targeted at coping with stressful parenting situations. Treatment will include weekly 2-hour sessions for 14 weeks.
Study: NCT01049360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg / Formoterol 12 μg
Description: Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg / Formoterol 6 μg
Description: Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
Study: NCT00316290

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Parent Training
Description: Parents will receive behavioral training. Treatment will include weekly 2-hour sessions for 14 weeks.
Study: NCT04307888

Intervention type: DEVICE
Intervention: Perclose Proglide (Abbott)
Description: Common Femoral Artery percutaneous access closure by means of Perclose Proglide device
Study: NCT01872923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphinex
Description: Photosensitiser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Anticancer agent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Laser that emits red light at 652 nm.
Study: NCT01049360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Description: Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol 12 μg
Description: Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
Study: NCT01847404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one
Description: Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two
Description: Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA 100 mg tablet
Description: Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
Study: NCT01220024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Collagen Sponge
Description: Drug: Bupivacaine Collagen Sponge
Study: NCT00264576

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine
Study: NCT00572013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: 375mg/m2 IV on days -20 to -8. Infusion to begin at rate of 50mg/hour for 1st hour.If no toxicity rate may be increased. A second infusion 375mg/m2 given 30days post transplant and again at 60 days post transplant
Study: NCT01220024

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo collagen Sponge
Description: Drug: Placebo Collagen Sponge
Study: NCT01247376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling and compression
Description: Cooling and compression of the knee postoperatively with an Aircast device.
Study: NCT04030364

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CrossFit group exercise classes
Description: The group classes will occur at a local CrossFit gym facility. Participants will be free to attend up to 6 regularly-scheduled, free, 1-hr group classes per week at the local exercise facility for a period of 3-months. The recommendation will be to aim to attend at least three classes/week but there will no prescribed minimum. Classes will be supervised by experienced trainers.~Trainers will work collaboratively with participants to adapt the skill and workout of the day within each group class to the individual participant's physical limitations and needs. As such, each participant may complete a slightly different movement or workout on any given day based on their functional status at that time. However, all participants will be actively included in the community of the group class and will experience a relative stimulus that is moderately challenging for them.
Study: NCT02632097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein Hernioplasty with Histoacryl
Description: Procedure/Surgery: Lichtenstein Hernioplasty with Histoacryl:~0.5 ml of cyanoacrylate glue is used for mesh fixation
Study: NCT00572013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM
Description: BCNU(carmustine)on day -6 300mg/M2 IV, etoposide 100mg/M2 BID on days -5 through -2, cytarabine 100mg/m2 BID on days -5 through -2, melphalan 140mg/m2 IV on day -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Description: following chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
Study: NCT01279616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate
Description: 180 mg/m2 over 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on day -13 and day -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: AUC 1000-1200 microM.mt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: 2.5 mg/kg for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg on day +3
Study: NCT01847404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg gastro-resistant tablet
Description: Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
Study: NCT02411825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01279616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 15 mg/kg q 8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.03 mg/kg /d
Study: NCT02181764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
Study: NCT03487185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
Study: NCT03275142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Icare tonometer
Description: Icare tonometry effects of keratometry readings, topography, and corneal staining to demonstrate that the Icare tonometer does not alter subsequent evaluation or testing. This would allow IOP testing to be performed by technical staff at any time during the examination process without affecting subsequent tests. A total of fifteen patients at each of four sites will be evaluated using Icare tonometers provided by Icare USA. The investigator will be masked as to which eye will undergo Icare tonometry. Both the study eye and the control eye will undergo pre-tonometry and post-tonometry testing; Keratometry readings, IOL master, Topography via Pentacam, and corneal staining with fluorescein using the Oxford scoring scale.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Icare tonometer
Description: Icare tonometry effects of keratometry readings, topography, and corneal staining to demonstrate that the Icare tonometer does not alter subsequent evaluation or testing. This would allow IOP testing to be performed by technical staff at any time during the examination process without affecting subsequent tests. A total of fifteen patients at each of four sites will be evaluated using Icare tonometers provided by Icare USA. The investigator will be masked as to which eye will undergo Icare tonometry. Both the study eye and the control eye will undergo pre-tonometry and post-tonometry testing; Keratometry readings, IOL master, Topography via Pentacam, and corneal staining with fluorescein using the Oxford scoring scale.
Study: NCT02550301

Intervention type: OTHER
Intervention: Mean Platelet Volume
Description: Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
Study: NCT01410903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSorb Ig
Description: 1,5 plasma volume per treatment venovenous immunoadsorption frequency: three times weekly in week 1 and 2, two times weekly in week 3-6, two times two-weekly in week 7-12 duration: 12 months
Study: NCT00709995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sunitinib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT03487185

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep Advice Control
Description: Initial sleep advice counseling alone
Study: NCT03282097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DECAD decision aid
Description: A mammography decision aid directed toward family caregivers of older women with Alzheimer's disease and other dementias to assist with decisions about breast cancer screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home safety guide
Description: The home safety guide to provide tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards.
Study: NCT02914574

Intervention type: OTHER
Group type: OTHER
Intervention: PowersTM strap
Description: The powers strap aims to decrease knee varus through supporting femoral abduction and external rotation. Participants will wear the Powers strap while performing functional tasks (running, squatting, single leg step down).
Study: NCT01720433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intervention
Description: The patient was placed in the Trendelenburg position (30°) and two manual lung inflations to a maximum pressure of 60 cm H2O for five seconds, with the valves on the operative ports fully open.
Study: NCT02308735

Intervention type: OTHER
Intervention: N/A - No intervention

Intervention type: OTHER
Intervention: N/A - No intervention
Study: NCT03515512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Enasidenib may help block the over production of IDH2, which when mutated, can overproduce metabolites and compounds that contribute to the growth of tumors and cancerous cells
Study: NCT04505969

Intervention type: OTHER
Intervention: Questionnaire to assess needs
Description: Two questionnaires have been developed to assess the specific needs of healthcare professionals working with SCD patients and of SCD patients or parents of children with SCD

Intervention type: OTHER
Intervention: Questionnaire to assess needs
Description: Two questionnaires have been developed to assess the specific needs of healthcare professionals working with SCD patients and of SCD patients or parents of children with SCD
Study: NCT01867528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic adhesiolysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open adhesiolysis
Study: NCT02964247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
Study: NCT03972761

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI) 3 tesla
Description: Functional neuroimaging objectifies the activation of specific areas of the brain

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI) 3 tesla
Description: Functional neuroimaging objectifies the activation of specific areas of the brain
Study: NCT01101815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Naltrexone
Description: 50 mg/day-oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Implant
Description: monthly-implant

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Drug Counseling Manual Driven
Description: Given to both groups biweekly, weeks 2 - 48. Counseling will consist of three components: 1) giving advice, support and clinical management aimed to maintain abstinence; 2) adherence enhancement to encourage keeping appointments, taking ART medications as prescribed and getting treatment for associated problems; and 3) reviewing behaviors that are likely to spread HIV and other infectious diseases, and counseling on how to stop them.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Drug Counseling Manual Driven
Description: Given to both groups biweekly, weeks 2 - 48. Counseling will consist of three components: 1) giving advice, support and clinical management aimed to maintain abstinence; 2) adherence enhancement to encourage keeping appointments, taking ART medications as prescribed and getting treatment for associated problems; and 3) reviewing behaviors that are likely to spread HIV and other infectious diseases, and counseling on how to stop them.
Study: NCT03733613

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04139356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep breaths
Description: Patients will undergo a 6 minutes protocol. Baseline: 1 minute normal breaths. Intervention: 1 minute with 10 deep breaths, 1 each 6 secs. Pulse-oxymetry will be continuously recorded.
Study: NCT04680429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP7214
Description: Participants will receive single and multiple ascending doses of RP7214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single and multiple ascending doses of matching placebo
Study: NCT01385241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ipod video
Description: This group will be asked to watch the video on their Ipod Touch in its entirety at least once per week during the first four weeks of the study, and as often as desired in weeks 5-12. The participants will be asked to record the times viewed and their feelings/comments in a viewing log, and will be given surveys at 30 and 90 days.
Study: NCT03151330

Intervention type: OTHER
Group type: OTHER
Intervention: Screened Arm
Description: Woman who are identified as high risk will be advised of potential interventions which will include support through care link(nurse education), cervical surveillance, consider vaginal progesterone, low dose aspirin if not already taking.
Study: NCT01625546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Hyperthermia system
Description: The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Whole Body Hyperthermia system
Description: The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.
Study: NCT03239444

Intervention type: DEVICE
Group type: OTHER
Intervention: Intracardiac echocardiography imaging
Description: Wide visualization of the the heart anatomy and additional devices used during atrial fibrillation ablation procedures.
Study: NCT02249611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile physical activity promotion tool
Description: 1. Mobile activity sensor~2. Smartphone with APP~3. Interactional webpage of internet~4. Evidence based health information~5. Individualized reminding messages according to the data from activity recording system~6. Personal counseling from professional personnel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Counseling on lifestyles with health education material
Study: NCT02463682

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CGM and Insulin Pump
Description: Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop Control System
Description: The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)
Study: NCT00626171

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allergen Challenge
Description: Allergen challenge
Study: NCT02540070

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor free

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor free with dex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Study: NCT00868127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate
Description: Participants from 01-04-TL-475-008 Monotherapy Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and additional lipid-lowering therapy
Description: Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.~Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks.